| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
69,710,000 |
| Market
Cap: |
19.45(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2465 - $0.6247 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Synlogic is a clinical-stage biopharmaceutical company applying synthetic biology to the discovery and development of synthetic biotic medicines. Co.'s pipeline includes SYNB1618 and SYNB1934, which are orally administered, non-systemically absorbed drug candidates being studied as potential treatments for phenylketonuria; SYNB1353, which is an orally administered, non-systemically absorbed drug candidate designed to consume methionine in the gastrointestinal tract thereby lowering homocysteine levels in patients with homocystinuria; and SYNB8802, which is an orally administered, non-systemically absorbed drug candidate being developed for the treatment of enteric hyperoxaluria.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
9,500 |
| Total Buy Value |
$0 |
$0 |
$0 |
$10,640 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
560 |
560 |
560 |
28,593 |
| Total Sell Value |
$969 |
$969 |
$969 |
$17,110 |
| Total People Sold |
2 |
2 |
2 |
4 |
| Total Sell Transactions |
2 |
2 |
2 |
5 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Miller Paul Francis |
Chief Scientific Officer |
• – – |
2019-02-12 |
4 |
AS |
$9.75 |
$30,722 |
D/D |
(3,151) |
53,984 |
|
- |
|
| Miller Paul Francis |
Chief Scientific Officer |
• – – |
2018-10-18 |
4 |
AS |
$9.77 |
$29,296 |
D/D |
(3,000) |
57,135 |
|
- |
|
| Miller Paul Francis |
Chief Scientific Officer |
• – – |
2018-09-18 |
4 |
AS |
$13.05 |
$39,163 |
D/D |
(3,000) |
60,135 |
|
- |
|
| Miller Paul Francis |
Chief Scientific Officer |
• – – |
2018-09-05 |
4 |
AS |
$12.55 |
$37,635 |
D/D |
(3,000) |
63,135 |
|
- |
|
| Miller Paul Francis |
Chief Scientific Officer |
• – – |
2018-08-30 |
4 |
AS |
$9.76 |
$13,092 |
D/D |
(1,342) |
66,135 |
|
- |
|
| Miller Paul Francis |
Chief Scientific Officer |
• – – |
2018-08-29 |
4 |
AS |
$9.77 |
$16,198 |
D/D |
(1,658) |
67,477 |
|
- |
|
| Miller Paul Francis |
Chief Scientific Officer |
• – – |
2018-07-18 |
4 |
AS |
$11.01 |
$33,022 |
D/D |
(3,000) |
69,135 |
|
- |
|
| Miller Paul Francis |
Chief Scientific Officer |
• – – |
2018-06-20 |
4 |
AS |
$9.75 |
$20,079 |
D/D |
(2,054) |
72,135 |
|
- |
|
| Miller Paul Francis |
Chief Scientific Officer |
• – – |
2018-06-19 |
4 |
AS |
$9.75 |
$9,224 |
D/D |
(946) |
74,189 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • – |
2018-01-26 |
4 |
A |
$9.75 |
$6,971,250 |
I/I |
715,000 |
2,029,996 |
|
- |
|
| Powell Michael |
Director |
– • – |
2018-01-26 |
4 |
A |
$9.75 |
$1,462,500 |
I/I |
150,000 |
574,972 |
|
- |
|
| Khuong Chau Quang |
Director |
– • – |
2018-01-26 |
4 |
A |
$9.75 |
$6,971,250 |
I/I |
715,000 |
2,029,996 |
|
- |
|
| Barrett M James |
10% Owner |
– – • |
2018-01-26 |
4 |
A |
$9.75 |
$3,997,500 |
I/I |
410,000 |
4,228,940 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2018-01-26 |
4 |
A |
$9.75 |
$3,997,500 |
I/I |
410,000 |
4,228,940 |
|
- |
|
| Nea Partners 14, L.p. |
10% Owner |
– – • |
2018-01-26 |
4 |
A |
$9.75 |
$3,997,500 |
D/D |
410,000 |
4,228,940 |
|
- |
|
| Viswanathan Ravi |
10% Owner |
– – • |
2018-01-26 |
4 |
A |
$9.75 |
$3,997,500 |
I/I |
410,000 |
4,228,940 |
|
- |
|
| Mott David M |
10% Owner |
– – • |
2018-01-26 |
4 |
A |
$9.75 |
$3,997,500 |
I/I |
410,000 |
4,228,940 |
|
- |
|
| Kerins Patrick J |
10% Owner |
– – • |
2018-01-26 |
4 |
A |
$9.75 |
$3,997,500 |
I/I |
410,000 |
4,228,940 |
|
- |
|
| Sonsini Peter W. |
10% Owner |
– – • |
2018-01-26 |
4 |
A |
$9.75 |
$3,997,500 |
I/I |
410,000 |
4,228,940 |
|
- |
|
| Florence Anthony A. Jr. |
10% Owner |
– – • |
2018-01-26 |
4 |
A |
$9.75 |
$3,997,500 |
I/I |
410,000 |
4,228,940 |
|
- |
|
| Barris Peter J |
10% Owner |
– – • |
2018-01-26 |
4 |
A |
$9.75 |
$3,997,500 |
I/I |
410,000 |
4,228,940 |
|
- |
|
| Baskett Forest |
10% Owner |
– – • |
2018-01-26 |
4 |
A |
$9.75 |
$3,997,500 |
I/I |
410,000 |
4,228,940 |
|
- |
|
| Kerins Patrick J |
10% Owner |
– – • |
2017-08-28 |
4 |
A |
$0.00 |
$0 |
I/I |
3,394,439 |
3,818,940 |
|
- |
|
| Mott David M |
10% Owner |
– – • |
2017-08-28 |
4 |
A |
$0.00 |
$0 |
I/I |
3,394,439 |
3,818,940 |
|
- |
|
| Brennan Aoife |
Chief Medical OfficerOfficer |
• – – |
2017-08-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
51,767 |
|
- |
|
128 Records found
|
|
Page 2 of 6 |
|
|
